Background: Colorectal cancer (CRC) ranks third among the most common cancers and one
in four CRC patients are diagnosed at metastatic stage. Metastatic colorectal cancer …

BACKGROUND: Treatment patterns for metastatic colorectal cancer (mCRC) patients have
changed considerably over the last decade with the introduction of new chemotherapies and …

Background Over the last decade, multiple chemotherapies/targeted biologics have been
approved for metastatic colorectal cancer (mCRC). However, evidence is limited with …

Colorectal cancer is a lethal disease if not discovered early. Even though appropriate
screening and preventive strategies are in place in many countries, a significant number of …

Background The treatment of patients with metastatic colorectal cancer (mCRC) has evolved
during the past 2 decades, and patient survival has increased. Consequently, patients are …

Background Many randomised trials have compared different systemic treatment regimens
in patients with advanced colorectal cancer. While survival advances have apparently been …

Objectives Data on healthcare management of patients with metastatic colorectal cancer
(mCRC) are scarce in France. A study was conducted to evaluate the feasibility of identifying …

Objectives To assess the value for money of alternative chemotherapy strategies for
managing advanced colorectal cancer using irinotecan or oxaliplatin, either in sequence or …

699 Background: Treatment (tx) selection for mCRC is multifactorial and affected by patient
(pt) and disease factors, comorbidities, and previous tx. Few agents existed for therapy after …

OBJECTIVES Colorectal cancer (CRC) ranks third in prevalence and cancer deaths among
all cancers in the United States. Nearly one fourth of CRC patients are diagnosed at …